AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 25, 2024
32254_dirs_2024-01-25_5a00a9b1-c38c-4711-91db-aa49deba5b2d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-01-23
Reporting Person: Lurker Nancy (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-23 | Common Stock | S | 5044.00 | $24.9702 | Disposed | 165397.00 | Direct |
| 2024-01-24 | Common Stock | S | 29956.00 | $24.9783 | Disposed | 135441.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-24 | Stock Option (Right to Buy) | $3.26 | G | 112700.00 | Disposed | 2033-01-05 | Common Stock (112700.00) | Direct |
| 2024-01-24 | Stock Option (Right to Buy) | $3.26 | G | 112700.00 | Acquired | 2033-01-05 | Common Stock (112700.00) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 52208.00 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.24. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company.
F5: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.